Header Logo

Connection

JOSEPH KHOURY to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications JOSEPH KHOURY has written about Biomarkers, Tumor.
JOSEPH KHOURY
Connection Strength
2.651
Biomarkers, Tumor
  1. The Journey to Improve the College of American Pathologists Cancer Biomarker Reporting Protocols. Arch Pathol Lab Med. 2024 Oct 01; 148(10):1105-1109.
    View in: PubMed
    Score: 0.249
  2. CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations. Leuk Res. 2021 09; 108:106614.
    View in: PubMed
    Score: 0.197
  3. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol. 2020 09; 44(9):1235-1243.
    View in: PubMed
    Score: 0.188
  4. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. 2019 10; 43(10):1429-1437.
    View in: PubMed
    Score: 0.176
  5. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection. Curr Hematol Malig Rep. 2019 10; 14(5):368-375.
    View in: PubMed
    Score: 0.176
  6. Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications. Curr Hematol Malig Rep. 2019 10; 14(5):353-357.
    View in: PubMed
    Score: 0.176
  7. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. 2018 10 19; 8(11):98.
    View in: PubMed
    Score: 0.165
  8. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018 06; 42(6):799-806.
    View in: PubMed
    Score: 0.161
  9. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. 2018 02 01; 24(3):521-531.
    View in: PubMed
    Score: 0.152
  10. The evolving potential of companion diagnostics. Scand J Clin Lab Invest Suppl. 2016; 245:S22-5.
    View in: PubMed
    Score: 0.141
  11. High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis. Am J Surg Pathol. 2016 Jan; 40(1):e1-16.
    View in: PubMed
    Score: 0.136
  12. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol. 2006 Apr; 208(5):624-32.
    View in: PubMed
    Score: 0.069
  13. Ewing sarcoma family of tumors. Adv Anat Pathol. 2005 Jul; 12(4):212-20.
    View in: PubMed
    Score: 0.066
  14. Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. J Pathol. 2022 01; 256(1):4-14.
    View in: PubMed
    Score: 0.051
  15. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. 2021 09; 35(9):2621-2634.
    View in: PubMed
    Score: 0.049
  16. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Curr Hematol Malig Rep. 2019 10; 14(5):358-367.
    View in: PubMed
    Score: 0.044
  17. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):324-333.
    View in: PubMed
    Score: 0.044
  18. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
    View in: PubMed
    Score: 0.042
  19. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
    View in: PubMed
    Score: 0.041
  20. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
    View in: PubMed
    Score: 0.040
  21. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2016 10; 91(10):1036-43.
    View in: PubMed
    Score: 0.035
  22. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016 Jun; 68(7):1090-8.
    View in: PubMed
    Score: 0.034
  23. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015 Jun; 28(6):787-98.
    View in: PubMed
    Score: 0.032
  24. Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med. 2015 Jan; 139(1):11-3.
    View in: PubMed
    Score: 0.032
  25. Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate. Arch Pathol Lab Med. 2010 Jan; 134(1):120-3.
    View in: PubMed
    Score: 0.022
  26. Identification of circulating tumor cells captured by the FDA-cleared Parsortix? PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):240.
    View in: PubMed
    Score: 0.015
  27. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024; 13(1):2388304.
    View in: PubMed
    Score: 0.015
  28. Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol. 2003 Oct; 34(10):1022-9.
    View in: PubMed
    Score: 0.015
  29. The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma. Ann Diagn Pathol. 2002 Jun; 6(3):154-8.
    View in: PubMed
    Score: 0.013
  30. Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol. 2020 Dec; 49:151636.
    View in: PubMed
    Score: 0.012
  31. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):367-379.
    View in: PubMed
    Score: 0.011
  32. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.010
  33. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018 09; 31(9):1470-1478.
    View in: PubMed
    Score: 0.010
  34. Characteristics and clinical implications of reactive germinal centers in the bone marrow. Hum Pathol. 2017 10; 68:7-21.
    View in: PubMed
    Score: 0.009
  35. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.
    View in: PubMed
    Score: 0.008
  36. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol. 2016 Apr; 50:109-17.
    View in: PubMed
    Score: 0.008
  37. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med. 2005 Aug; 129(8):990-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.